BGI Genomics Co Ltd

On September 24, major A-share indices opened lower, while the media sector bucked the trend in early trading. Xinhua Winshare hit its fifth consecutive limit-up, Xinhua Media its fourth, and Topway Video its third, with Guangdong Media and Inner Mongolia Xinhua Distribution also among the top gainers. In news, Xinhua Winshare recently announced plans to use its own funds to acquire the 100% equity stake in Sichuan Nationalities Publishing House held by its controlling shareholder, Sichuan Xinhua Publishing and Distribution Group, for 346 million yuan. The transaction constitutes a related-party transaction but does not constitute a major asset restructuring. On the same day, Bairui Gene debuted on the Beijing Stock Exchange, opening 347.23% higher and rising more than 400% as of press time, with an issue price of 16.77 yuan. The company focuses on the research, production, and sales of biomedical materials and other products. The AI-driven drug discovery concept saw a sudden surge, with Berry Genomics hitting the daily limit-up in a straight line, and BGI Genomics, Rongtai Health, Saili Medical, Sino Biological, and Kingmed Diagnostics following higher. This came after the Ministry of Industry and Information Technology and nine other departments jointly issued the 15th Five-Year Plan for the development of the pharmaceutical industry, which explicitly calls for accelerating the use of artificial intelligence and other new technologies to empower drug research and development. The coal sector fluctuated higher, with Yunnan Coal Energy hitting the daily limit-up, briefly opening, and then sealing the limit-up again. Zhengzhou Coal Mining Machinery, Liaoning Energy, Antai Group, and Shaanxi Heimao followed higher. On September 24, the benchmark price for thermal coal on SunSirs was 989.50 yuan per ton, up 13.02% from 875.50 yuan per ton at the beginning of the month. The robotics concept saw localized movement, with Xiangyang Automobile Bearing hitting the limit-up, and Ningbo Dongli, Wanxiang Qianchao, Nanfang Precision, Sanhua Intelligent Controls, and Tuopu Group following higher. Tesla CEO Elon Musk said in an interview on September 23 that he predicts there will be at least 1 billion humanoid robots within 10 years or less, perhaps 10 billion in the next 15 years, and possibly 100 billion in the next 20 years. The real estate sector fell sharply, with Huali Family hitting the limit-down, Huayuan Holdings touching the limit-down, and Greenland Holdings, Heungkong Holdings, China Vanke, and Risesun Development quickly following lower.

BGI Genomics released its 2026 semi-annual report, achieving operating revenue of 1.789 billion yuan, up 9.59% year on year. Net profit attributable to shareholders of the listed company was 47.4046 million yuan, up 718.24% year on year. The company's second-quarter net profit was 57 million yuan, while first-quarter net profit was negative 10 million yuan. Based on this calculation, second-quarter net profit turned from a loss to a profit quarter on quarter.

BGI Genomics has completed the third phase of its share buyback plan through centralized competitive trading. As of August 5, 2026, the company had repurchased a total of 6.7316 million shares, accounting for 1.61% of the current total share capital, with a total payment of 251 million yuan. The buyback implementation period was from July 13 to August 5, 2026, with the highest transaction price at 40.00 yuan per share and the lowest at 35.33 yuan per share. The actual total funds used exceeded the lower limit of 250 million yuan set in the buyback plan but did not exceed the upper limit of 500 million yuan. The repurchased shares will be used entirely for employee stock ownership plans or equity incentives, and will not carry voting rights or other shareholder rights during the holding period.

BGI Genomics announced that it has repurchased a total of 4.27 million shares through centralized competitive trading, accounting for 1.0208% of the total share capital. The total repurchase amount was 154 million yuan, with the repurchase price ranging from 35.33 yuan to 36.87 yuan per share. In the first quarter of 2026, the company achieved revenue of 809 million yuan and a net loss attributable to the parent company of 9.52 million yuan.

Bangkok Genomics Innovation Public Company Limited, or BKGI, is moving forward with expanding its comprehensive genetic testing platform by leveraging technology transfer from BGI Group, a global leader in genomics, to support the rapidly growing precision medicine and genetic testing market. Dr. Saowalak Dansakul, Chief Executive Officer, stated that the company aims to broaden its customer base to hospitals, public health agencies, and the private sector, while building recurring revenue from reagent sales and post-installation services for genetic testing equipment. Mr. Kittikun Rodrangnok, Chief Financial Officer, disclosed that BKGI has allocated an investment budget of approximately 40 million baht to expand its technology platform and is targeting revenue growth of 20 to 30 percent in 2026 compared to the previous year, driven by the expansion of precision medicine services and growth in recurring revenue.

The Fourth China International Supply Chain Expo has opened its Healthy Life Chain section, drawing more than 100 leading companies across Medical Technology, Quality Living, and Heritage Wellness zones. Global players GE Healthcare and Siemens Healthineers are demonstrating full China-for-China R&D and manufacturing capabilities, while AstraZeneca features an AI-powered drug discovery platform. Chinese innovators including BGI with a human genome foundation model and Longwood Valley with a domestically produced orthopedic surgical robot are also taking center stage. In consumer health, Procter & Gamble, L'Oréal, Panasonic, and Starbucks are showcasing digital intelligence and sustainability in their supply chains, with Starbucks connecting directly to Yunnan coffee farms for full traceability. Chinese TCM brands such as Guangzhou Phar. Holdings, Xin Bao Tang, and Zhendong Pharmaceutical are accelerating global expansion and vertical integration of authentic herb supply chains, alongside AI-driven diagnostic tools like smart pulse-taking devices.